Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis.
Systemic Mastocytosis (SM) is a clonal disease characterized by abnormal accumulation of mast cells in multiple organs. Clinical presentations of the disease vary widely from indolent to aggressive forms, and to the exceedingly rare mast cell leukemia. Current treatment of aggressive SM and mast cel...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0096209&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850191534310293504 |
|---|---|
| author | Serena De Vita Rebekka K Schneider Michael Garcia Jenna Wood Mathilde Gavillet Benjamin L Ebert Alexander Gerbaulet Axel Roers Ross L Levine Ann Mullally David A Williams |
| author_facet | Serena De Vita Rebekka K Schneider Michael Garcia Jenna Wood Mathilde Gavillet Benjamin L Ebert Alexander Gerbaulet Axel Roers Ross L Levine Ann Mullally David A Williams |
| author_sort | Serena De Vita |
| collection | DOAJ |
| description | Systemic Mastocytosis (SM) is a clonal disease characterized by abnormal accumulation of mast cells in multiple organs. Clinical presentations of the disease vary widely from indolent to aggressive forms, and to the exceedingly rare mast cell leukemia. Current treatment of aggressive SM and mast cell leukemia is unsatisfactory. An imatinib-resistant activating mutation of the receptor tyrosine kinase KIT (KIT D816V) is most frequently present in transformed mast cells and is associated with all clinical forms of the disease. Thus the etiology of the variable clinical aggressiveness of abnormal mast cells in SM is unclear. TET2 appears to be mutated in primary human samples in aggressive types of SM, suggesting a possible role in disease modification. In this report, we demonstrate the cooperation between KIT D816V and loss of function of TET2 in mast cell transformation and demonstrate a more aggressive phenotype in a murine model of SM when both mutations are present in progenitor cells. We exploit these findings to validate a combination treatment strategy targeting the epigenetic deregulation caused by loss of TET2 and the constitutively active KIT receptor for the treatment of patients with aggressive SM. |
| format | Article |
| id | doaj-art-7857a9f7de7c4ea89650b596a89f3907 |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-7857a9f7de7c4ea89650b596a89f39072025-08-20T02:14:54ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0195e9620910.1371/journal.pone.0096209Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis.Serena De VitaRebekka K SchneiderMichael GarciaJenna WoodMathilde GavilletBenjamin L EbertAlexander GerbauletAxel RoersRoss L LevineAnn MullallyDavid A WilliamsSystemic Mastocytosis (SM) is a clonal disease characterized by abnormal accumulation of mast cells in multiple organs. Clinical presentations of the disease vary widely from indolent to aggressive forms, and to the exceedingly rare mast cell leukemia. Current treatment of aggressive SM and mast cell leukemia is unsatisfactory. An imatinib-resistant activating mutation of the receptor tyrosine kinase KIT (KIT D816V) is most frequently present in transformed mast cells and is associated with all clinical forms of the disease. Thus the etiology of the variable clinical aggressiveness of abnormal mast cells in SM is unclear. TET2 appears to be mutated in primary human samples in aggressive types of SM, suggesting a possible role in disease modification. In this report, we demonstrate the cooperation between KIT D816V and loss of function of TET2 in mast cell transformation and demonstrate a more aggressive phenotype in a murine model of SM when both mutations are present in progenitor cells. We exploit these findings to validate a combination treatment strategy targeting the epigenetic deregulation caused by loss of TET2 and the constitutively active KIT receptor for the treatment of patients with aggressive SM.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0096209&type=printable |
| spellingShingle | Serena De Vita Rebekka K Schneider Michael Garcia Jenna Wood Mathilde Gavillet Benjamin L Ebert Alexander Gerbaulet Axel Roers Ross L Levine Ann Mullally David A Williams Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. PLoS ONE |
| title | Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. |
| title_full | Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. |
| title_fullStr | Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. |
| title_full_unstemmed | Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. |
| title_short | Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. |
| title_sort | loss of function of tet2 cooperates with constitutively active kit in murine and human models of mastocytosis |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0096209&type=printable |
| work_keys_str_mv | AT serenadevita lossoffunctionoftet2cooperateswithconstitutivelyactivekitinmurineandhumanmodelsofmastocytosis AT rebekkakschneider lossoffunctionoftet2cooperateswithconstitutivelyactivekitinmurineandhumanmodelsofmastocytosis AT michaelgarcia lossoffunctionoftet2cooperateswithconstitutivelyactivekitinmurineandhumanmodelsofmastocytosis AT jennawood lossoffunctionoftet2cooperateswithconstitutivelyactivekitinmurineandhumanmodelsofmastocytosis AT mathildegavillet lossoffunctionoftet2cooperateswithconstitutivelyactivekitinmurineandhumanmodelsofmastocytosis AT benjaminlebert lossoffunctionoftet2cooperateswithconstitutivelyactivekitinmurineandhumanmodelsofmastocytosis AT alexandergerbaulet lossoffunctionoftet2cooperateswithconstitutivelyactivekitinmurineandhumanmodelsofmastocytosis AT axelroers lossoffunctionoftet2cooperateswithconstitutivelyactivekitinmurineandhumanmodelsofmastocytosis AT rossllevine lossoffunctionoftet2cooperateswithconstitutivelyactivekitinmurineandhumanmodelsofmastocytosis AT annmullally lossoffunctionoftet2cooperateswithconstitutivelyactivekitinmurineandhumanmodelsofmastocytosis AT davidawilliams lossoffunctionoftet2cooperateswithconstitutivelyactivekitinmurineandhumanmodelsofmastocytosis |